What the company does
Tego Science develops and supplies cell therapy products, treatments that use living cells to address conditions such as burns, foot ulcers, skin wrinkles, and tendon injuries at a biological level.
Its approved products are used in clinical and hospital settings in South Korea, and it also provides contract development, manufacturing, and quality-testing services to other cell-therapy developers. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds multiple cell-therapy approvals from Korea's drug regulator and operates its own GMP-certified manufacturing facility, making contract services a growing part of its business alongside its own products.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$5.6M
- FY2024US$4.9M
- FY2025US$4.3M
Operating profit
- FY2023−US$860.8K
- FY2024−US$1.6M
- FY2025−US$3.2M
Net income
- FY2023−US$1.7M
- FY2024US$2.4M
- FY2025−US$5.1M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company holds regulatory approval for three cell-therapy products covering five indications from Korea's Ministry of Food and Drug Safety, a relatively rare position in the domestic market.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?